Previous close | 50.09 |
Open | 50.65 |
Bid | 0.00 x 2200 |
Ask | 0.00 x 3100 |
Day's range | 50.30 - 51.64 |
52-week range | 38.82 - 61.71 |
Volume | |
Avg. volume | 25,009,375 |
Market cap | 289.568B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 14.74 |
EPS (TTM) | 3.50 |
Earnings date | 02 May 2022 - 06 May 2022 |
Forward dividend & yield | 1.60 (3.21%) |
Ex-dividend date | 12 May 2022 |
1y target est | 59.33 |
NEW YORK & MAINZ, Germany, June 25, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted
NEW YORK, June 24, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2022 Performance Report, to be issued that morning.
EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.